Treatment of Acute Falciparum Malaria With Sulfalene and Trimethoprim

Abstract

The combination of a long-acting sulfonamide, sulfalene, and a dihydrofolic acid reductase inhibitor, trimethoprim, proved to be effective as a radical cure against a normal, as well as a chloroquine-quinine-pyrimethamine-resistant<i>Plasmodium falciparum</i>in nonimmune volunteers. The malaria caused by normal<i>P falciparum</i>was cured (eight of eight cases) by sulfalene (0.25 gm) plus trimethoprim (0.125 gm) administered as a single dose. Sulfalene (0.75 gm) plus trimethoprim (0.5 gm) combined cured ten of 11 patients with malaria caused by chloroquine-pyrimethamine-quinine-resistant<i>P falciparum</i>. Attempts to induce resistance to the combination have been unsuccessful thus far. The speed of action in clearance of parasites and lysis of fever compares favorably with that of chloroquine at its best. The combination is easily tolerated as a single dose.